SCS Capital Management LLC Acquires Shares of 99,000 Annexon, Inc. $ANNX

SCS Capital Management LLC bought a new position in shares of Annexon, Inc. (NASDAQ:ANNX) during the second quarter, HoldingsChannel.com reports. The firm bought 99,000 shares of the company’s stock, valued at approximately $565,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ANNX. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after buying an additional 2,785 shares in the last quarter. Susquehanna Portfolio Strategies LLC increased its stake in Annexon by 0.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after acquiring an additional 2,875 shares during the period. ProShare Advisors LLC raised its holdings in Annexon by 21.7% in the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock valued at $124,000 after acquiring an additional 4,410 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Annexon by 3.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 134,786 shares of the company’s stock valued at $747,000 after acquiring an additional 4,684 shares in the last quarter. Finally, Comerica Bank lifted its position in shares of Annexon by 26.4% during the 3rd quarter. Comerica Bank now owns 32,357 shares of the company’s stock valued at $99,000 after acquiring an additional 6,750 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday. Wall Street Zen downgraded Annexon from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Annexon in a research report on Monday, July 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Annexon has an average rating of “Hold” and a consensus price target of $15.33.

Annexon Price Performance

NASDAQ ANNX opened at $5.29 on Monday. The business has a fifty day moving average price of $5.35 and a two-hundred day moving average price of $5.50. The stock has a market capitalization of $1.00 billion, a PE ratio of -4.56 and a beta of 1.18. Annexon, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $7.18.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). As a group, sell-side analysts expect that Annexon, Inc. will post -1 earnings per share for the current year.

Insiders Place Their Bets

In other Annexon news, Director Muneer A. Satter bought 613,497 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were purchased at an average price of $5.41 per share, for a total transaction of $3,319,018.77. Following the completion of the transaction, the director directly owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. The trade was a 6.31% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.31% of the stock is owned by company insiders.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $14 price target, substantially above the stock’s recent trading level near $5.29. The firm continues to project a path to profitability, with estimated positive EPS of $0.03 in 2029 and $0.45 in 2030. HC Wainwright earnings estimates and rating
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, while WallStreetZen separately lowered its rating. The conflicting actions point to more cautious or mixed views among analysts rather than a clear change in the company’s fundamental outlook. Citizens JMP rating update WallStreetZen rating update
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030, including Q3 2026 EPS to a $0.27 loss from a $0.22 loss, FY2026 to a $0.99 loss from $0.90, and FY2029 earnings to $0.03 from $0.13. The firm also cut its FY2030 estimate to $0.45 from $0.56. These revisions suggest higher expected losses or slower financial improvement. Annexon recently reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate. HC Wainwright revised estimates

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.